Last reviewed · How we verify
Auris Medical AG — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Intranasal Drug | Intranasal Drug | marketed | ||||
| AM-101 | AM-101 | phase 3 | NMDA receptor antagonist | NMDA receptor | Otolaryngology / Neurology |
Therapeutic area mix
- Otolaryngology / Neurology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ajou University School of Medicine · 1 shared drug class
- Alameda Health System · 1 shared drug class
- American University of Beirut Medical Center · 1 shared drug class
- Asker & Baerum Hospital · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Beijing Tiantan Hospital · 1 shared drug class
- Celon Pharma SA · 1 shared drug class
- Acacia Pharma Ltd · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Auris Medical AG:
- Auris Medical AG pipeline updates — RSS
- Auris Medical AG pipeline updates — Atom
- Auris Medical AG pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Auris Medical AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/auris-medical-ag. Accessed 2026-05-17.